LILYPADD TRIAL: TARGETING HIPPOCAMPAL HYPERCONNECTIVITY IN COGNITIVELY NORMAL OLDER ADULTS AT RISK FOR ALZHEIMER’S DISEASE WITH AGB101.

levetiracetam low dose (AGB101) - AgeneBio

S.J. Li1; A. Bakker2; B.D. Ward3; Y. Wang4; S. Schold5; P. Antuono5; E.D. Granadillo5; M. Franczak5; J. Goveas6

Oct 5, 2022